Information for patients prescribed Bramitob

Bramitob contains an antibiotic called tobramycin which helps fight chest infections caused by Pseudomonas aeruginosa in cystic fibrosis (CF) patients ≥6 years of age. Pseudomonas aeruginosa is a common bacterium that affects patients with CF.#

Your healthcare professional has prescribed Bramitob to help manage your lung infection.

This page is designed to give you some key information about using Bramitob, but please remember to read the Patient Information Leaflet inside the pack before starting your treatment.

The importance of managing chronic lung infections in cystic fibrosis
  • Despite recent advancements in cystic fibrosis care, the use of treatments that target chronic airways infections will continue to be an important part of cystic fibrosis care.*
  • Chronic Pseudomonas aeruginosa airway infection can lead to an inflammatory response and affect the ability of the lungs to function.
  • Chronic lung infections are long-term infections which are difficult to treat.
  • You probably have several medications to help with your CF. However, only inhaled antibiotics are proven to manage chronic Pseudomonas aeruginosa lung infections.
  • If you have chronic Pseudomonas aeruginosa in your lungs it is important to take your inhaled antibiotics because they are specifically designed to manage these infections.
  • You may start to feel better and feel that you no longer need your inhaled antibiotics, however you should not stop taking your inhaled antibiotics unless told to do so by your CF team.
  • If you do not take your inhaled antibiotics you will not be managing your chronic lung infections and this could lead to further respiratory complications.**

In the video below, you will learn more about how CF affects the fluid that lines the airways and lungs. In patients with CF, there is a build-up of mucus in the airways which is thick and sticky.

This traps germs which can lead to an infection. Antibiotics like Bramitob work to fight the germs that cause infection.

Supporting information:

* Bell S et al. The future of cystic fibrosis: a global perspective. Lancet Resp. 2020;8:65-124.
† Lyczak JB et al. Lung Infections Associated with Cystic Fibrosis: Clinical microbiology reviews. Apr. 2002; 15(2):194–222.
‡ NICE guideline [NG78]. Cystic fibrosis: diagnosis and management. 25 October 2017.
** Nichols DP et al. Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities. Ann Am Thorac Soc. 2019 May; 16(5): 534–539.

What is Bramitob?
  • Bramitob contains an antibiotic called tobramycin. It belongs to the group of antibiotics called aminoglycosides.
What does Bramitob do?
  • Bramitob is an inhaled antibiotic used to manage chronic lung infections caused by Pseudomonas aeruginosa in people with cystic fibrosis who are 6 years old or over.
When should Bramitob be taken?
  • You should take Bramitob twice a day, with doses taken as close to 12 hours apart as possible.
  • Each course is to be taken for 28 days. You then have 28 days without taking Bramitob, before starting another 28-day treatment cycle.
  • You should keep taking Bramitob in the way your doctor has told you, until they tell you to stop.
How should I take Bramitob?
  • You should inhale the contents of one container in the morning and one in the evening.
  • Bramitob should be taken through a clean, dry PARI LC PLUS or PARI LC SPRINT reusable nebuliser (for your own personal use only) and a suitable compressor. Ask your doctor or physiotherapist for advice on which compressor to use.
  • Filters pads can also be used in a filter/valve set. Filter pads prevent inhaled medication escaping when you exhale, protecting members of your family or people you live with. They can also stop sticky antibiotic residue getting on your furniture and surfaces.*

Supporting information:

* Daniels et al. CF Trust, Inhaled therapy for people with cystic fibrosis Factsheet – May 2016.

How long does it take to inhale each dose of Bramitob?
  • One dose of Bramitob is nebulised in about 15 minutes.
How should I store Bramitob?
  • You can store your Bramitob in a refrigerator (2-8°C) or Bramitob bags (intact or opened) may be stored for up to 3 months at no more than 25°C.
  • Store your containers in the original packaging, in order to protect them from light.
What should I do if I miss a dose?
  • If you forget a dose, take it as soon as you remember as long as there is at least 6 hours before your next dose.
  • However, if there is less than 6 hours until your next dose, skip the missed dose.
  • Do not inhale the contents of more than one container to make up for a missed dose.
Does my Nebuliser need cleaning?
  • Your nebuliser will need cleaning and disinfecting after each dose. For a step by step guide please refer to the instructions provided with the nebuliser.
What are the possible side effects?
  • The tobramycin in Bramitob is one of a group of medicines that can occasionally cause hearing loss and dizziness.
  • It is important that you tell your healthcare professional as soon as possible if you experience either of these or any other side effects while taking Bramitob.
  • Kidney damage has also been associated with tobramycin and at risk patients should therefore consult their doctor.
  • If you would like information about other potential side effects, please see the patient information leaflet which is provided with your Bramitob, an online version of this can be found here.
Can my medicine be delivered to me?
  • In the UK, it may be possible for you to receive Bramitob via a homecare delivery service, please ask your CF Team for more details.
  • Remember you should always ask a member of your CF team if you have any questions about your CF or medication(s).

Always take your Bramitob treatment as prescribed by your healthcare professional.
If you stop taking Bramitob for any reason, you should tell your doctor as soon as possible.
Remember, you should always ask a member of your CF team if you have any questions
about your CF or your medication(s).


Supporting information: Bramitob® Patient Information Leaflet, Chiesi Limited.
# UK Cystic Fibrosis Registry Annual Data Report 2019, Published August 2020.

IE-CF-2000141 | Nov 2020